Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Pharma Climbing Aboard Digital Health Train, But Not Up To Speed?

Executive Summary

The still somewhat loosely defined concept of 'digital health' continues to take concrete forms through recent deals in Japan, where major pharma firms are building initiatives related mainly to patient well-being.

You may also be interested in...



Arteryex Acquisition To Enhance Eisai's Digital Strategy

Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.

China’s Internet Hospitals And New Commercial Models For Pharma

Pharma is leveraging new commercial models in China as part of strategies to offset centralized procurements-induced market share losses and also for new launches, the co- founder of Indegene, a healthtech solutions provider, tells Scrip. He also shares insights on how companies in Japan are shifting digital gears amid COVID-19.

Digital Health Trends: Asia Catching Up But Hurdles Remain

Digital health initiatives are rapidly emerging in Asia amid robust innovation and rising R&D activities in the region, but there are still some hurdles to overcome. An executive from Pfizer talks to Scrip about some of the major trends, opportunities and challenges.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC124329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel